• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Evaluation of Efficacy of Oral Terbinafine versus Itraconazole in Treatment of Dermatophytic Skin Infections at a Tertiary Care Hospital

    Amit Singhal, Kumar Raja Madasu, Vinay Sharma, Anand

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 1430-1433

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Superficial dermatophytosis affecting hair, skin and nail are common public health problem in India, because of the tropical climate with heat and humidity. The present study was conducted to assess efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin.
Materials & Methods: The patients were randomly divided into two groups to receive a daily dose of terbinafine 500 mg daily for 4 weeks (Group I) or 200 mg of itraconazole for 4 weeks daily (Group II). Patients were followed up after 2 weeks and 4 weeks of the study period. At each visit, clinical response was noted including pruritus, erythema, and scaling. All analysis was done SPSS version 21.0 (IBM Corp., Armonk, NY).
Results: A total of 100 patient were randomly divided into two groups to receive a daily dose of terbinafine 500 mg daily for 4 weeks (Group II) or 200 mg of itraconazole for 4 weeks daily (Group I). At baseline in group I erythema was severe in maximum patients, scaling, pruritus was moderate in maximum patients. At 2nd week in group I erythema, pruritus was moderate in maximum patients, scaling was mild in maximum patients. At 4th week in group I erythema, pruritus was mild in maximum patients, scaling was absent in maximum patients. At baselie in group II erythema was equally moderate and severe in maximum patients, scaling, pruritus was moderate in maximum patients. At 2nd week in group II erythema was moderate in maximum patients, scaling and pruritus was mild in maximum patients. At 4th week in group I erythema, pruritus was mild in maximum patients, scaling was absent in maximum patients.
Conclusion: The present study concluded that Itraconazole has higher clinical and mycological cure rates as compared to terbinafine. erythema and scaling was absent in more patients in group I than group II.
Keywords:
    Itraconazole Terbinafine Dermatophytosis
  • PDF (268 K)
  • XML
(2022). Evaluation of Efficacy of Oral Terbinafine versus Itraconazole in Treatment of Dermatophytic Skin Infections at a Tertiary Care Hospital. European Journal of Molecular & Clinical Medicine, 9(3), 1430-1433.
Amit Singhal, Kumar Raja Madasu, Vinay Sharma, Anand. "Evaluation of Efficacy of Oral Terbinafine versus Itraconazole in Treatment of Dermatophytic Skin Infections at a Tertiary Care Hospital". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 1430-1433.
(2022). 'Evaluation of Efficacy of Oral Terbinafine versus Itraconazole in Treatment of Dermatophytic Skin Infections at a Tertiary Care Hospital', European Journal of Molecular & Clinical Medicine, 9(3), pp. 1430-1433.
Evaluation of Efficacy of Oral Terbinafine versus Itraconazole in Treatment of Dermatophytic Skin Infections at a Tertiary Care Hospital. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 1430-1433.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 2
  • PDF Download: 12
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus